Skip to content

Evaluation of the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV)

Prospective Randomized Controlled Trial to Evaluate the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV) in Singleton Pregnancy in Breech Presentation at Term

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01948115
Acronym
MEOREV
Enrollment
150
Registered
2013-09-23
Start date
2013-11-01
Completion date
2015-12-01
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breech Presentation in Pregnancy

Keywords

Breech presentation, equimolar mixture of oxygen and nitrous oxide, external cephalic version

Brief summary

The variety of breech presentation at term is about 3-4% of all births. Our study aims to assess the value of using an equimolar mixture of oxygen and nitrous oxide. Indeed, in some patients algic or relaxed, the success rate seems more important. It's a single blind prospective randomized controlled study, comparing success rate of ECV after an equimolar mixture of oxygen and nitrous oxide or placebo (medical air). We need to include 150 patients (75 in each arm), for a period of 2 years. After ECV, we will give the patient a satisfaction questionnaire. We compare the success rate of ECV as primary outcome.

Interventions

DRUGequimolar mixture of oxygen and nitrous oxide or medical air

We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group "placebo" (medical air), 75 patients in group "treatment" (equimolar mixture of oxygen and nitrous oxide). Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention.

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18 years * pregnancy at term (≥36 weeks) * singleton foetus in breech or transverse presentation * acceptance of ECV * signature of informed consent

Exclusion criteria

* contraindications of ECV: placenta praevia, obstacle praevia, multiple pregnancy, foetal death, foetal heart rhythm disorder, lack of amniotic fluid, HIV-positive patient * contraindications of equimolar mixture of oxygen and nitrous oxide : patient who require pure oxygen ventilation, disorders of consciousness that impede the cooperation of the patient, pneumothorax, pulmonary embolism, ocular surgery

Design outcomes

Primary

MeasureTime frameDescription
Number of women with success after ECV20 minutesSuccess rate just after ECV between the two groups (equimolar mixture of oxygen and nitrous oxide group, and medical air group) with ultrasound.

Secondary

MeasureTime frameDescription
Pain during ECV20 minutesJust after ECV: pain during ECV with Visual Analogue Scale
Frequency of nausea/vomiting1 hourJust after ECV: Frequency of nausea / vomiting between the two groups
Number of interrupted procedures20 minutesJust after ECV: number of interrupted procedures due to pain
Number of cephalic presentation at birth2 monthAt birth: rate of cephalic presentation between the two groups
Number of cesarean at birth2 monthAt birth: cesarean rate between the two groups

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJulie ESBELIN, Dr

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026